Novel dual agonist peptide analogues derived from dogfish glucagon show promising in vitro insulin releasing actions and antihyperglycaemic activity in mice

Molecular and Cellular Endocrinology

Volumn 431, Issue , 2016, Pages 133-144

  O'Harte, F P M ^a   Ng, M T ^a   Lynch, A M ^a   Conlon, J M ^a   Flatt, P R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Acute effects; Antidiabetic and antihyperglycaemic; Diabetes; Dogfish glucagon; Dual agonist; Glucagon; Glucagon like peptide 1 (GLP 1); Glucose dependent insulinotropic polypeptide (GIP)

Indexed keywords

ANTIDIABETIC AGENT; CYCLIC AMP; EXENDIN 4; EXENDIN 4[1-39]; EXENDIN 4[31-39]; EXENDIN 4[9-39]; GASTRIC INHIBITORY POLYPEPTIDE RECEPTOR; GLUCAGON; GLUCAGON DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON RECEPTOR; GLUCOSE; INSULIN; UNCLASSIFIED DRUG; GASTRIC INHIBITORY POLYPEPTIDE; HORMONE RECEPTOR; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIABETES MELLITUS; DOGFISH; GLUCOSE HOMEOSTASIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INSULIN RELEASE; LIPID DIET; MALE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RAT; ANIMAL; C57BL MOUSE; CELL LINE; DRUG EFFECTS; HAMSTER; HEK293 CELL LINE; KNOCKOUT MOUSE; METABOLISM;

ANIMALS; CELL LINE; CRICETINAE; DOGFISH; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HEK293 CELLS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PEPTIDES; RECEPTORS, GASTROINTESTINAL HORMONE; RECEPTORS, GLUCAGON;

EID: 84969498350     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2016.05.012     Document Type: Article

References (66)

1. Al-Sabah S., Donnelly D. A model for receptor-peptide binding at the glucagon-like peptide-1 (GLP-1) receptor through the analysis of truncated ligands and receptors. Br. J. Pharmacol. 2003, 140:339-346.
2. Ahren B. Enhancement or the prolongation of GLP-1 activity as a strategy for treatment of type 2 diabetes. Drug Discov. Today Ther. Strateg. 2004, 1:207-212.
3. Bhat V.K., Kerr B.D., Flatt P.R., Gault V.A. A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties. Biochem. Pharmacol. 2013, 85:1655-1662.
4. Bhat V.K., Kerr B.D., Vasu S., Flatt P.R., Gault V.A. A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice. Diabetologia 2013, 56:1417-1424.
5. Campbell J.E., Drucker D.J. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013, 17:819-837. Review.
6. Charron M.J., Vuguin P.M. Lack of glucagon receptor signaling and its implications beyond glucose homeostasis. J. Endocrinol. 2015, 224:R123-R130.
7. Claus T.H., Pan C.Q., Buxton J.M., Yang L., Reynolds J.C., Barucci N., Burns M., Ortiz A.A., Roczniak S., et al. Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes. J. Endocrinol. 2007, 192:371-380.
8. Conlon J.M., O'Toole L., Thim L. Primary structure of glucagon from the gut of the common dogfish, Scyliorhinus canicula. FEBS Lett. 1987, 214:50-56.
9. Day J.W., Ottaway N., Patterson J.T., Gelfanov V., Smiley D., Gidda J., Findeisen H., Bruemmer D., Drucker D.J., et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat. Chem. Biol. 2009, 5:749-757.
10. Drucker D.J. Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes 2013, 62:3316-3323. (Review).
11. Falkmer S., Van Noorden S. Ontogeny and phylogeny of the glucagon cell. Handbook of Experimental Pharmacology 1983, 66/I:81-119. Springer-Verlag, Heidelberg.
12. Finan B., Ma T., Ottaway N., Müller T.D., Habegger K.M., Heppner K.M., Kirchner H., Holland J., Hembree J., et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci. Transl. Med. 2013, 5. 209ra151.
13. Flatt P.R., Bailey C.J. Development of glucose intolerance and impaired plasma insulin response to glucose in obese hyperglycaemic (ob/ob) mice. Horm. Metab. Res. 1981, 13:556-560.
14. Fosgerau K., Jessen L., Lind Tolborg J., Østerlund T., Schæffer Larsen K., Rolsted K., Brorson M., et al. The novel GLP-1-gastrin dual agonist, ZP3022, increases β-cell mass and prevents diabetes in db/db mice. Diabetes Obes. Metab. 2013, 15:62-71.
15. Franklin Z.J., McDonnell B., Montgomery I.A., Flatt P.R., Irwin N. Dual modulation of GIP and glucagon action by the low molecular weight compound 4-hydroxybenzoic acid 2-bromobenzylidene hydrazide. Diabetes Obes. Metab. 2011, 13:742-749.
16. Gault V.A., Porter D.W., Irwin N., Flatt P.R. Comparison of sub-chronic metabolic effects of stable forms of naturally occurring GIP(1-30) and GIP(1-42) in high-fat fed mice. J. Endocrinol. 2011, 208:265-271.
17. Gelling R.W., Du X.Q., Dichmann D.S., Romer J., Huang H., Cui L., Obici S., Tang B., Holst J.J., et al. Lower blood glucose, hyperglucagonemia, and pancreatic α cell hyperplasia in glucagon receptor knockout mice. Proc. Nat. Acad. Sci. U. S. A. 2003, 100:1438-1443.
18. 8-substituted GLP-1 analogues. Biol. Chem. 2004, 385:169-177.
19. Green B.D., Irwin N., Gault V.A., Bailey C.J., O'Harte F.P.M., Flatt P.R. Chronic treatment with exendin(9-39)amide indicates a minor role for endogenous glucagon-like peptide-1 in metabolic abnormalities of obesity-related diabetes in ob/ob mice. J. Endocrinol. 2005, 185:307-317.
20. Gremlich S., Porret A., Hani E.H., Cherif D., Vionnet N., Froguel P., Thorens B. Cloning, functional expression, and chromosomal localization of the human pancreatic islet glucose-dependent insulinotropic polypeptide receptor. Diabetes 1995, 44:1202-1208.
21. Habegger K.M., Heppner K.M., Geary N., Bartness T.J., DiMarchi R., Tschöp M.H. The metabolic actions of glucagon revisited. Nat. Rev. Endocrinol. 2010, 6:689-697. Review.
22. Hinke S.A., Pospisilik J.A., Demuth H.U., Mannhart S., Kühn-Wache K., Hoffmann T., Nishimura E., Pederson R.A., McIntosh C.H. Dipeptidyl peptidase IV (DPIV/CD26) degradation of glucagon. Characterization of glucagon degradation products and DPIV-resistant analogs. J. Biol. Chem. 2000, 275:3827-3834.
23. Hogan A.E., Tobin A.M., Ahern T., Corrigan M.A., Gaoatswe G., Jackson R., O'Reilly V., Lynch L., Doherty D.G., et al. Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis. Diabetologia 2011, 54:2745-2754.
24. Holst J.J. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors. Expert Opin. Emerg. Drugs 2004, 9:155-166. (Review).
25. Holz G.G., Chepurny O.G. Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus. Curr. Med. Chem. 2003, 10:2471-2483. Review.
26. Inagaki N., Kuromi H., Seino S. PACAP/VIP receptors in pancreatic beta-cells: their roles in insulin secretion. Ann. N. Y. Acad. Sci. 1996, 805:44-51.
27. Irwin D.M., Huner O., Youson J.H. Lamprey proglucagon and the origin of glucagon-like peptides. Mol. Biol. Evol. 1999, 16:1548-1557.
28. Irwin N., Green B.D., Mooney M.H., Greer B., Harriott P., Bailey C.J., Gault V.A., O'Harte F.P.M., Flatt P.R. A novel, long-acting agonist of glucose-dependent insulinotropic polypeptide suitable for once-daily administration in type 2 diabetes. J. Pharmacol. Exp. Ther. 2005, 314:1187-1194.
29. Irwin N., Flatt P.R. New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disorders. World J. Diabetes 2015, 6:1285-1295.
30. Irwin N., Pathak V., Flatt P.R. A novel CCK-8/GLP-1 hybrid peptide exhibiting prominent insulinotropic, glucose-lowering, and satiety actions with significant therapeutic potential in high-fat-fed mice. Diabetes 2015, 64:2996-3009.
31. Kela R., Davies M.J. Treatment evaluation of liraglutide in type 2 diabetes. Expert Opin. Biol. Ther. 2012, 12:1551-1556. Review.
32. Kerr B.D., Irwin N., O'Harte F.P.M., Bailey C.J., Flatt P.R., Gault V.A. Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Biochem. Pharmacol. 2009, 78:1008-1016.
33. Knudsen L.B. Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes. J. Med. Chem. 2004, 47:4128-4134.
34. Kopin A.S., Wheeler M.B., Nishitani J., McBride E.W., Chang T.M., Chey W.Y., Leiter A.B. The secretin gene: evolutionary history, alternative splicing, and developmental regulation. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:5335-5339.
35. Kurtzhals P., Havelund S., Jonassen I., Kiehr B., Larsen U.D., Ribel U., Markussen J. Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem. J. 1995, 312:725-731.
36. Lennox R., Porter D.W., Flatt P.R., Gault V.A. (Val(8))GLP-1-Glu-PAL: a GLP-1 agonist that improves hippocampal neurogenesis, glucose homeostasis, and β-cell function in high-fat-fed mice. Chem. Med. Chem. 2013, 8:595-602.
37. Madsbad S. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)-preclinical and clinical results. Best. Prac. Res. Clin. Endocrinol. Metab. 2009, 23:463-477.
38. McClenaghan N.H., Barnett C.R., Ah-Sing E., Abdel-Wahab Y.H., O'Harte F.P., Yoon T.W., Swanston-Flatt S.K., Flatt P.R. Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion. Diabetes 1996, 45:1132-1140.
39. McCormack P.L. Exenatide twice daily: a review of its use in the management of patients with type 2 diabetes mellitus. Drugs 2014, 74:325-351. Review.
40. Miyawaki K., Yamada Y., Yano H., Niwa H., Ban N., Ihara Y., Kubota A., Fujimoto S., Kajikawa M., et al. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:14843-14847.
41. Nauck M. Incretin therapies - highlighting common features and differences in the modes of action of GLP-1 receptor agonists and DPP-4 inhibitors. Diabetes Obes. Metab. 2015 Oct 22, ([Epub ahead of print]). 10.1111/dom.12591.
42. Nikfar S., Abdollahi M., Salari P. The efficacy and tolerability of exenatide in comparison to placebo; a systematic review and meta-analysis of randomized clinical trials. J. Pharm. Pharm. Sci. 2012, 15:1-30. (Review).
43. O'Harte F.P.M., Hunter K., Gault V.A., Irwin N., Green B.D., Greer B., Harriott P., Bailey C.J., Flatt P.R. Antagonistic effects of two novel GIP analogs, (Hyp3)GIP and (Hyp3)GIPLys16PAL, on the biological actions of GIP and longer-term effects in diabetic ob/ob mice. Am. J. Physiol. Endocrinol. Metab. 2007, 292:E1674-E1682.
44. O'Harte F.P.M., Franklin Z.J., Rafferty E.P., Irwin N. Characterisation of structurally modified analogues of glucagon as potential glucagon receptor antagonists. Mol. Cell. Endocrinol. 2013, 381:26-34.
45. Parker J.C., Irwin N., Lavery K.S., Green B.D., O'Harte F.P.M., Gault V.A., Flatt P.R. Metabolic effects of sub-chronic ablation of the incretin receptors by daily administration of (Pro3)GIP and exendin(9-39)amide in obese diabetic (ob/ob) mice. Biol. Chem. 2007, 388:221-226.
46. Pathak V., Gault V.A., Flatt P.R., Irwin N. Antagonism of gastric inhibitory polypeptide (GIP) by palmitoylation of GIP analogues with N- and C-terminal modifications improves obesity and metabolic control in high fat fed mice. Mol. Cell. Endocrinol. 2015, 401:120-129.
47. Plisetskaya E.M., Mommsen T.P. Glucagon and glucagon-like peptides in fishes. Int. Rev. Cytol. 1996, 168:187-257.
48. Pocai A. Unraveling oxyntomodulin, GLP1's enigmatic brother. J. Endocrinol. 2012, 235:335-346.
49. Pocai A., Carrington P.E., Adams J.R., Wright M., Eiermann G., Zhu L., Du X., Petrov A., Lassman M.E., et al. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes 2009, 58:2258-2266.
50. Pospisilik J.A., Hinke S.A., Pederson R.A., Hoffmann T., Rosche F., Schlenzig D., Glund K., Heiser U., McIntosh C.H., Demuth H. Metabolism of glucagon by dipeptidyl peptidase IV (CD26). Regul. Pept. 2001, 96:133-141.
51. Ramnanan C.J., Edgerton D.S., Kraft G., Cherrington A.D. Physiologic action of glucagon on liver glucose metabolism. Diabetes Obes. Metab 2011, 13:118-125. (Review).
52. Sadry S.A., Drucker D.J. Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. Nat. Rev. Endocrinol. 2013, 2013(9):425-433.
53. Scott L.J. Liraglutide: a review of its use in adult patients with type 2 diabetes mellitus. Drugs 2014, 74:2161-2174. Review.
54. Scrocchi L.A., Brown T.J., MaClusky N., Brubaker P.L., Auerbach A.B., Joyner A.L., Drucker D.J. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat. Med. 1996, 2:1254-1258.
55. Skarbaliene J., Secher T., Jelsing J., Ansarullah, Neerup T.S., Billestrup N., Fosgerau K. The anti-diabetic effects of GLP-1-gastrin dual agonist ZP3022 in ZDF rats. Peptides 2015, 69:47-55.
56. Surwit R.S., Kuhn C.M., Cochrane C., McCubbin J.A., Feinglos M.N. Diet-induced type II diabetes in C57BL/6J mice. Diabetes 1988, 37:1163-1167.
57. Tan T.M., Field B.C., McCullough K.A. Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes 2013, 62:1131-1138.
58. Thorens B., Porret A., Bühler L., Deng S.P., Morel P., Widmann C. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 1993, 42:1678-1682.
59. Tom I., Lee V., Dumas M., Madanat M., Ouyang J., Severs J., Andersen J., Buxton J.M., Whelan J.P., Pan C.Q. Reproducible production of a PEGylated dual-acting peptide for diabetes. AAPS J. 2007, 9:E227-E234.
60. Trebbien R., Klarskov L., Olesen M., Holst J.J., Carr R.D., Deacon C.F. Neutral endopeptidase 24.11 is important for the degradation of both endogenous and exogenous glucagon in anesthetized pigs. Am. J. Physiol. Endocrinol. Metab. 2004, 287:E431-E438.
61. Trevaskis J.L., Mack C.M., Sun C., Soares C.J., D'Souza L.J., Levy O.E., Lewis D.Y., Jodka C.M., Tatarkiewicz K., et al. Improved glucose control and reduced body weight in rodents with dual mechanism of action peptide hybrids. PLoS One 2013, 8:e78154.
62. Turner N., Kowalski G.M., Leslie S.J., Risis S., Yang C., Lee-Young R.S., Babb J.R., Meikle P.J., Lancaster G.I., et al. Distinct patterns of tissue-specific lipid accumulation during the induction of insulin resistance in mice by high-fat feeding. Diabetologia 2013, 56:1638-1648.
63. Werle M., Bernkop-Schnürch A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids 2006, 30:351-367. (Review).
64. Winzell M.S., Ahren B. The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes 2004, 53:S215-S219.
65. Wysham C., Grimm M., Chen S. Once weekly exenatide: efficacy, tolerability and place in therapy. Diabetes Obes. Metab. 2013, 15:871-881.
66. Ye L., Robertson M.A., Hesselson D., Stainier D.Y., Anderson R.M. Glucagon is essential for alpha cell transdifferentiation and beta cell neogenesis. Development 2015, 142:1407-1417.